Interaction of homocysteine, glutathione and 8-hydroxy-2′-deoxyguanosine in metabolic syndrome progression

Butkowski, Eugene; Al-Aubaidy, Hayder A.; Jelinek, Herbert F.

doi:10.1016/j.clinbiochem.2016.10.006

Cited by 15 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study cross-sectionally examined the relationship of plasma Hcy to the autonomic nervous system in OSAS individuals. Evidence exists in the literature that Hcy is associated with diverse parameters of subclinical cardiovascular diseases such as atherosclerosis, metabolic syndrome, and endothelial dysfunction [1,17]. Our findings extend these observations by demonstrating that elevated Hcy levels are closely associated with dysfunction of the autonomic nervous system independent of potential confounders among individuals of OSAS.…”

Section: Discussionsupporting

confidence: 84%

“…Accumulating evidence suggests that abnormally elevated level of homocysteine (Hcy) is prevalent and an independent risk factor for various cardiovascular diseases and metabolic diseases [1,2]. Hcy is a sulfur-containing nonconstitutive amino acid that is derived from the essential amino acid methionine, which is synthesized during metabolic conversion of methionine to cysteine in the liver [3].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma Homocysteine and Autonomic Nervous Dysfunction: Association and Clinical Relevance in OSAS

Liu

Yan

et al. 2020

Disease Markers

View full text Add to dashboard Cite

Objective. Elevated plasma homocysteine (Hcy) is an independent risk factor for cardiovascular diseases, but the precise mechanism of Hcy in cardiovascular disease remains elusive. This study is aimed at evaluating the association between Hcy levels and autonomic nervous system and at investigating their clinical relevance in obstructive sleep apnea syndrome (OSAS). Methods. A total of 191 subjects with OSAS were enrolled for this cross-sectional study. Heart rate variability (HRV) represents the status of the autonomic nervous system and is a well-known index that allows studying the autonomic modulation. HRV and polysomnography parameters were collected based on Holter monitors and polysomnography system. The software computed all the basic HRV parameters including SDANN, SDNN and pNN50. Correlation analyses between Hcy and HRV parameters and echocardiographic parameters were performed. Results. Compared with the mild-moderate OSAS group, the prevalence of male and smoking and Hcy levels were considerably higher in the severe OSAS group (P=0.01, P=0.02, and P=0.01, respectively). Also, there were significant linear relationships between Hcy quartiles with the proportion of severe OSAS (P=0.01 for the trend). Interesting, there is a negative linear correlation between SDANN and Hcy quartiles (P=0.02 for the trend). Spearman’s correlation analysis showed a significant negative correlation between SDANN and Hcy levels (r=−0.17, P=0.02). Interestingly, the relationship of it remains significant after adjustment for clinical covariates (r=−0.15, P=0.04). However, echocardiographic parameters were not significantly correlated with Hcy or HRV parameters (all P>0.05). Conclusions. Elevated plasma Hcy level is linearly correlated with cardiac autonomic nervous function disorders in patients with OSAS.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Plasma Homocysteine and Autonomic Nervous Dysfunction: Association and Clinical Relevance in OSAS

Liu

Yan

et al. 2020

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Studies, summarized in Table 5, show also that Type 2 DM is a condition of increased oxidative stress [44,45,103,[107][108][109].…”

Section: -Chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)mentioning

confidence: 99%

“…While the FRAP assay was originally developed to investigate antioxidant power in biological samples, such as plasma and urine, it has since been applied to foods and health products, and since it is a test for the intrinsic chemical antioxidant properties of an agent, it was applied to drugs in this instance [42,43]. Studies by other investigators have shown that these drugs used in the management of DM can improve antioxidant status and ameliorate oxidative stress in cell culture, animal, and human trials (Table 4) [44,45].…”

Section: -Chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)mentioning

confidence: 99%

Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Choi

2017

Redox Report

View full text Add to dashboard Cite

Objectives: This is a narrative review, investigating the antioxidant properties of drugs used in the management of diabetes, and discusses whether these antioxidant effects contribute to, confound, or conceal the effects of antioxidant therapy. Methods: A systematic search for articles reporting trials, or observational studies on the antioxidant effect of drugs used in the treatment of diabetes in humans or animals was performed using Web of Science, PubMed, and Ovid. Data were extracted, including data on a number of subjects, type of treatment (and duration) received, and primary and secondary outcomes. The primary outcomes were reporting on changes in biomarkers of antioxidants concentrations and secondary outcomes were reporting on changes in biomarkers of oxidative stress. Results: Diabetes Mellitus is a disease characterized by increased oxidative stress. It is often accompanied by a spectrum of other metabolic disturbances, including elevated plasma lipids, elevated uric acid, hypertension, endothelial dysfunction, and central obesity. This review shows evidence that some of the drugs in diabetes management have both in vivo and in vitro antioxidant properties through mechanisms such as scavenging free radicals and upregulating antioxidant gene expression. Conclusion: Pharmaceutical agents used in the treatment of type 2 diabetes has been shown to exert an antioxidant effect..

show abstract

“…The most common therapy for treatment of T2DM involves the use of hypoglycemic agents (sulfonylureas, nonsulfonylureas, secretagogues, biguanides, and thiozolidinediones), lipid-lowering agents, and antihypertensive medications [1]. Some of these drugs have been shown to exhibit antioxidant properties and pleiotropic effects in cell culture, experimental animals, and human trials [8]. Variations in the mechanisms of action of these drugs may also result in their differential effects on various metabolic processes in T2DM, which may also reflect on the levels of some biochemical indices used in diagnosis and monitoring of diabetes progression.…”

Section: Introductionmentioning

confidence: 99%

Hypoglycemic Agents and Changes in Oxidative Stress Indices, Electrolytes, and Cardiovascular Risk Factors in Type 2 Diabetes

Nsonwu-Anyanwu

Nsonwu

Usoro

2019

Dubai Diabetes Endocrinol J

View full text Add to dashboard Cite

Background: Metabolic complications of type 2 diabetes (T2DM), including dyslipidemia, electrolyte imbalance, and oxidative stress, have been shown to be modulated by hypoglycemic agents. Objective: The lipid profile, electrolytes, and oxidative stress indices were evaluated in T2DM. Methods: Fifty T2DM patients on metformin (n = 23), insulin (n = 17), and insulin/metformin (n = 10) and 40 controls were studied. Fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), total antioxidant capacity (TAC), total plasma peroxide (TPP), and total calcium (Ca) values were determined colorimetrically, sodium (Na+) and potassium (K+) levels were determined by flame photometry, chloride (Cl–) and bicarbonate (HCO3–) levels were determined by titration, and low-density lipoprotein cholesterol (LDL-C) levels, the atherogenic index of plasma (AIP), and the oxidative stress index (OSI) were determined by calculation. Data were analyzed using t test, analysis of variance, and Pearson’s correlation at p < 0.05. Results: T2DM patients had higher lipid peroxidation (TPP and OSI), atherogenic lipids (higher LDL-C and AIP and lower HDL-C), and lower antioxidants compared to controls (p < 0.05). T2DM patients with poor glycemic control had higher lipid peroxidation (higher TPP) and atherogenic lipids (TG and AIP) compared to those with good control (p < 0.05). Patients with T2DM for >5 years had higher protein glycosylation (higher HBA1c) and TC compared to those with T2DM for <5 years (p < 0.05). The class of hypoglycemic agent has no effect on the levels of all of the biochemical indices studied (p > 0.05). HDL-C correlated negatively with TG (r = –0.347, p = 0.013), LDL-C (r = –0.322, p = 0.018), and AIP (r = –0.714, p = 0.000) in T2DM. Conclusion: Chronic T2DM and poor glycemic control are associated with reduced antioxidants, lipid peroxidation, and atherogenic dyslipidemia. Different hypoglycemic agents exert no differential effects on the metabolic indices of T2DM studied.

show abstract

Interaction of homocysteine, glutathione and 8-hydroxy-2′-deoxyguanosine in metabolic syndrome progression

Cited by 15 publications

References 35 publications

Plasma Homocysteine and Autonomic Nervous Dysfunction: Association and Clinical Relevance in OSAS

Plasma Homocysteine and Autonomic Nervous Dysfunction: Association and Clinical Relevance in OSAS

Antioxidant properties of drugs used in Type 2 diabetes management: could they contribute to, confound or conceal effects of antioxidant therapy?

Hypoglycemic Agents and Changes in Oxidative Stress Indices, Electrolytes, and Cardiovascular Risk Factors in Type 2 Diabetes

Contact Info

Product

Resources

About